Multi-nuclear platinum drugs: A new paradigm in chemotherapy

Current Medicinal Chemistry - Anti-Cancer Agents

Volumn 5, Issue 3, 2005, Pages 267-279

  Wheate, Nial J ^a,b   Collins, J Grant ^b  

^a Joint Health Support Agency   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Anti cancer; BBR3005; BBR3464; BBR3571; BBR3610; Chemotherapy; Multi nuclear; Platinum

Indexed keywords

AMD 0473; AMD 494; AMD 508; AMD0473; AMD494; AMD508; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BBR 3005; BBR 3464; BBR 3571; BBR 3610; BORON 10; CARBOPLATIN; CARBORANE DERIVATIVE; CISPLATIN; DRUG BINDING PROTEIN; EMETIC AGENT; JM 0473; JM0473; LOPERAMIDE; MANNITOL; MISMATCH REPAIR PROTEIN PMS2; NEW DRUG; OXALIPLATIN; PLASMA PROTEIN; PLATINUM DERIVATIVE; PROTEIN P53; SATRAPLATIN; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; BASE MISPAIRING; BONE MARROW TOXICITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL DEATH; CLINICAL TRIAL; COLON CANCER; CONFORMATIONAL TRANSITION; CYTOTOXICITY; DIARRHEA; DNA ADDUCT; DNA BINDING; DNA CROSS LINKING; DNA REPAIR; DNA TRANSCRIPTION; DRUG ACCUMULATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG POTENTIATION; DRUG RESPONSE; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERANCE; ELECTROLYTE DISTURBANCE; ENCAPSULATION; EYE TOXICITY; GASTROINTESTINAL TOXICITY; GENE CONTROL; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; HYDRATION; HYDROGEN BOND; HYPERURICEMIA; IN VITRO STUDY; IN VIVO STUDY; LEUKOPENIA; MESOTHELIOMA; NAUSEA; NEPHROTOXICITY; NEUROBLASTOMA; NEUROTOXICITY; NEUTRON CAPTURE THERAPY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; OVARY CANCER; OVARY CARCINOMA; PROSTATE CANCER; RECTUM CANCER; REVIEW; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VOMITING; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DNA ADDUCTS; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 18444405560     PISSN: 15680118     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568011053765994     Document Type: Review

References (131)

1. Rosenberg, B.; Van Camp, L.; Trosko, J.E.; Mansour, V.H. Nature, 1969, 222, 385.
2. Kelland, L.R.; Farrell, N.; Ed. Platinum Based Drugs in Cancer Therapy, Humana Press: New Jersey, 2000.
3. Lippert, B.; Ed. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, Wiley-VCH: New York, 1999.
4. Kleinwächter, V. Studia Biophys., 1978, 73, 1.
5. Roberts, J.J.; Thomson, A.J. Prog. Nucleic Acids Res. Mol. Biol., 1979, 22, 71.
6. Drobník, J. Cancer Chemother. Pharmacol., 1983, 10, 145.
7. Jamieson, E.R.; Lippard, S.J. Chem. Rev., 1999, 9, 2467.
8. Wong, E.; Giandomenico, C.M. Chem. Rev., 1999, 9, 2451.
9. Kelland, L.R. Drugs, 2000, 59, 1.
10. Baird, R.D.; Kaye, S.B. Eur. J. Cancer, 2003, 39, 2450.
11. Reedijk, J. Chem. Rev., 1999, 9, 2499.
12. AMD494 contains a pyridine ring, with the chloro ligands in the platinum in the trans configuration. AMD508 contains the 2, 6-dimethylpyridine ligand.
13. Holford, J.; Raynaud, F.; Murrer, B.A.; Grimaldi, K.; Hartley, J.A.; Abrams, M.; Kelland, L.R. Anti-Cancer Drug Des., 1998, 13, 1.
14. Raynaud, F.I.; Boxall, F.E.; Goddard, P.M.; Valenti, M.; Jones, M.; Murrer, B.A.; Abrams, M.; Kelland, L.R. Clin. Can. Res., 1997, 3, 2063.
15. Hay, M. Curr. Opin. Oncol. Endo. Meta. Invest. Drugs, 1999, 1, 443.
16. Holford, J.; Sharp, S.Y.; Murrer, B.A.; Abrams, M.; Kelland, L.R. Brit. J. Cancer, 1998, 77, 366.
17. Sharp, S.Y.; O'Neill, C.F.; Rogers, P.; Boxall, F.E.; Kelland, L.R. Eur. J. Cancer, 2002, 38, 2309.
18. Anormed Product Profile: AMD0473 June 2004.
19. Hartman, J.T.; Lipp, H.-P. Expert Opin. Pharmacother., 2003, 4, 889.
20. Cisplatin is currently sold around the world as an oncology drug by Bristol Myers-Squibb under the brand name Platinol™ and under the generic name CISplatin by Bedford. Sold as an aqueous solution (1 mg/mL with 9 mg/mL NaCl) it is used in the treatment of metastatic testicular tumours, metastatic ovarian tumours and advanced bladder cancer. Cisplatin is used as either a single agent, or in combination therapy with a range of other oncology drugs. Federal Drug Agency Product Label, Platinol, Oct 1999.
21. Federal Drug Agency Product Label, Paraplatin, Jun 2001.
22. For a review of oxaliplatin see: Cassidy, J. Int. J. Cancer Prevent., 2000, 54, 399.
23. Rixe, O.; Ortuzar, W.; Alverez, M. Biochem. Pharmacol., 1996, 52, 1855.
24. Raymond, B.; Faivre, S.; Woynarowski, J.M. Semin. Oncol., 1998, 25, 1.
25. Schmidt, W.; Chaney, S.G. Cancer Res., 1993, 53, 799.
26. Federal Drug Agency Product Label, Eloxatin, Jan 2004.
27. Farrell, N.P.; de Almeida, S.G.; Skov, K.A. J. Am. Chem. Soc., 1988, 110, 5018.
28. Farrell, N.; Qu, Y.; Hacker, M.P. J. Med. Chem., 1990, 33, 2179.
29. Farrell, N.; Qu, Y. Inorg. Chem., 1989, 28, 3416.
30. Skov, K.A.; Adomat, H.; Farrell, N.P.; Matthews, J.B. Anti-Cancer Drug Des., 1998, 13, 207.
31. Broomhead, J.A.; Lynch, M.J. Inorg. Chim. Acta, 1995, 240, 13.
32. Broomhead, J.A.; Rendina, L.M.; Sterns, M. Inorg. Chem., 1992, 31, 1880.
33. Broomhead, J.A.; Rendina, L.M.; Webster, L.K. J. Inorg. Biochem., 1993, 49, 221.
34. Farrell has an abbreviation scheme that relates the number of chloro ligands and their geometry on the metal complex in regard to the bridging linker. A complex with one chloro ligand on each platinum, trans to the bridging linker is referred to as 1,1/t,t. A complex with two cis chloro ligands is 2,2/c,c. A complex with one cis chloro ligand on the first platinum and two trans chloro ligands on the second platinum would be referred to as 1,2/c,t.
35. Qu, Y.; Appleton, T.G.; Hoeschele, J.D.; Farrell, N. Inorg. Chem., 1993, 32, 2591.
36. Qu, Y.; de Almeida, S.G.; Farrell, N. Inorg. Chim. Acta, 1992, 201, 123.
37. Kharatishvili, M.; Mathieson, M.; Farrell, N. Inorg. Chim. Acta, 1997, 225, 1.
38. Rauter, H.; Di Domenico, R.; Menta, E.; Oliva, A.; Qu, Y.; Farrell, N. Inorg. Chem., 1997, 36, 3919.
39. Qu, Y.; Rauter, H.; Soares Fontes, A.P.; Bandarage, R.; Kelland, L. R.; Farrell, N. J. Med. Chem., 2000, 43, 3189.
40. Hegmans, A.; Qu, Y.; Kelland, L.R.; Roberts, J.D.; Farrell, N. Inorg. Chem., 2001, 40, 6108.
41. Qu, Y.; Fitzgerald, J.A.; Rauter, H.; Farrell, N. Inorg. Chem., 2001, 40, 6324.
42. Jansen, B.A.J.; van der Zwan, J.; den Dulk, H.; Brouwer, J.; Reedijk, J. J. Med. Chem., 2001, 44, 245.
43. Farrell, N.; Qu, Y.; Feng, L.; Van Houten, B. Biochemistry, 1990, 29, 9522.
44. Sharp, S.Y.; Kelland, L.R. Curr. Opin. Oncol. Endo. Meta. Invest. Drugs, 2000, 2, 353.
45. Pratesi, G.; Perego, P.; Polizzi, D.; Righetti, S.C.; Supino, R.; Caserini, C.; Manzotti, C.; Giuliani, F.C.; Pezzoni, G.; Tognella, S.; Spinelli, S.; Farrell, N.; Zunino, F. Brit. J. Cancer, 1999, 80, 1912.
46. Perego, P.; Caserini, C.; Gatti, L.; Carenini, N.; Romanelli, S.; Supino, R.; Colangelo, D.; Viano, I.; Leone, R.; Spinelli, S.; Pezzoni, G.; Manzotti, C.; Farrell, N.; Zunino, F. Mol. Pharm., 1999, 55, 528.
47. Di Blasi, P.; Bernareggi, A.; Beggiolin, G.; Piazzoni, L.; Menta, E.; Formento, M.L. Anticancer Res., 1998, 18, 3113.
48. Orlandi, L.; Colella, G.; Bearzatto, A.; Abolafio, G.; Manzotti, C.; Daidone, M.G.; Zaffaroni, N. Eur. J. Cancer, 2001, 37, 649.
49. Colella, G.; Pennati, M.; Bearzatto, A.; Leone, R.; Colangelo, D.; Manzotti, C.; Daidone, M.G.; Zaffaroni, N. Brit. J. Cancer, 2001, 84, 1387.
50. Roberts, J.D.; Peroutka, J.; Beggiolin, G.; Manzotti, C.; Piazzoni, L.; Farrell, N. J. Inorg. Biochem., 1999, 77, 47.
51. Roberts, J.D.; Peroutka, J.; Farrell, N. J. Inorg. Biochem., 1999, 77, 51.
52. Manzotti, C.; Pratesi, G.; Menta, E.; Di Domenico, R.; Cavalletti, E.; Fiebig, H.H.; Kelland, L.R.; Farrell, N.; Polizzi, D.; Supino, R.; Pezzoni, G.; Zunino, F. Clin. Cancer Res., 2000, 6, 2626.
53. Riccardi, A.; Meco, D.; Ferlini, C.; Servidei, T.; Carelli, G.; Segni, G.; Manzotti, C.; Riccardi, R. Cancer Chem. Pharm., 2001, 47, 498.
54. Perego, P.; Gatti, L.; Caserini, C.; Supino, R.; Colangelo, D.; Leone, R.; Spinelli, S.; Farrell, N.; Zunino, F. J. Inorg. Biochem., 1999, 77, 59.
55. Perego, P.; Zunino, F.; Carenini, N.; Giuliani, F.; Spinelli, S.; Howell, S.B. Mol. Pharm., 1998, 54, 213.
56. Wheate, N.J.; Cullinane,C.; Webster, L.K.; Collins, J.G. Anti-Cancer Drug Des., 2001, 16, 91.
57. Zhao, G.; Lin, H.; Zhu, S.; Sun, H.; Chen. Y. Anti-Cancer Drug Des., 1998, 13, 769.
58. Zhao, G.; Lin, H.; Yu, P.; Sun, H.; Zhu, S.; Chen, Y. Chemico-Bio. Inter., 1998, 116, 19.
59. Cesar, E.T.; de Almeida, M.V.; Soares Fontes, A.P.; Maia, E.C.P.; Garnier-Suillerot, A.; Couri, M.R.C.; de Castro Antunes Felicio, E. J. Inorg. Biochem., 2003, 95, 297.
60. Bierbach, U.; Roberts, J.D.; Farrell, N. Inorg. Chem., 1998, 37, 717.
61. Zhao, G.; Lin, H.; Zhu, S.; Sun, H.; Chen, Y. J. Inorg. Biochem., 1998, 70, 219.
62. Jansen, B.A.J.; van der Zwan, J.; Reedijk, J.; den Dulk, H.; Brouwer, J. Eur. J. Inorg. Chem., 1999, 1429.
63. Komeda, S.; Lutz, M.; Spek; A.L.; Yamanaka, Y.; Sato, T.; Chikuma, M.; Reedijk, J. J. Am. Chem. Soc., 2002, 124, 4738.
64. Komeda, S.; Lutz, M.; Spek, A.L.; Chikuma, M.; Reedijk, J. Inorg. Chem., 2000, 39, 4230.
65. Komeda, S.; Ohishi, H.; Yamane, H.; Harikawa, M.; Sakaguchi, K.-I.; Chikuma, M. Dalton Trans., 1999, 2959.
66. These drugs are currently being developed by Cell Technologies Inc (CTI) which merged with Novuspharma SpA in January 2004. Roche retains it right to first refusal over the drugs.
67. Piccart, M.J.; Lamb, H.; Vermorken, J.B. Ann. Oncol., 2001, 12, 1195.
68. Boulikas, T.; Vougiouka, M. Oncol. Reports, 2003, 10, 1663.
69. Servidei, T.; Ferlini, C.; Riccardi, A.; Meco, D.; Scambia, G.; Segni, G.; Manzotti, C.; Riccardi, R. Eur. J. Cancer, 2001, 37, 930.
70. Kasparkova, J.; Vrana, O.; Farrell, N.; Brabec, V. J. Inorg. Biochem., 2004, 98, 1560.
71. Perego, P.; Gatti, L.; Righetti, S.C.; Beretta, G.L.; Carenini, N.; Corna, E.; Dal Bo, L.; Tinelli, S.; Colangelo, D.; Leone, R.; Apostoli, P.; Lombardi, L.; Beggiolin, G.; Piazzoni, L.; Zunino, F. Int. J. Cancer, 2003, 105, 617.
72. Cleare, M.J.; Hoeschele, J.D. Plat. Met. Rev., 1973, 17, 3.
73. Cleare, M.J.; Hoeschele, J.D. Bioinorg. Chem., 1973, 2, 187.
74. Sessa, C.; Capri, G.; Gianni, L.; Peccatori, F.; Grasselli, G.; Bauer, J.; Zucchetti, M.; Vigano, L.; Gatti, A.; Liati, P.; Van den Bosch, S.; Bernareggi, A.; Camboni, G.; Marsoni, S. Ann. Oncol., 2000, 11, 977.
75. Jodrell, D.I.; Evans, T.R.J.; Steward, W.; Cameron, D.; Prendiville, J.; Aschele, C.; Noberasco, C.; Lind, M.; Carmichael, J.; Dobbs, N.; Camboni, G.; Gatti, B.; De Brand F. Eur. J. Cancer, 2004, 40, 1872.
76. Calvert, A.H.; Thomas, H.; Colombo, N.; Gore, M.; Earl, H.; Sena, L.; Camboni, G.; Liati, P.; Sessa, C. Eur. J. Cancer, 2001, 37, S260.
77. Scagilotti, G.; Novello, S.; Crino, L.; De Marinia, F.; Tonato, M.; Noberasco, C.; Selvaggi, G.; Massoni, F.; Gatti, B.; Camboni, G. Lung Cancer, 2003, 41, S223.
78. Wheate, N.J.; Collins, J.G. J. Inorg. Biochem., 2000, 78, 313.
79. Wheate, N.J.; Webster, L.K.; Brodie, C.R.; Collins, J.G. Anti-Cancer Drug Des., 2000, 15, 313.
80. Neidle, S. DNA Structure and Function, IRL Press: Oxford, 1994.
81. Wheate, N.J.; Cutts, S.M.; Phillips, D.R.; Aldrich-Wright, J.R.; Collins, J.G. J. Inorg. Biochem., 2001, 84, 119.
82. Wang, Y.; Farrell, N.; Burgess, J.D. J. Am. Chem. Soc., 2001, 123, 5576.
83. Berners-Price, S.J.; Davies, M.S.; Cox, J.W.; Thomas, D.S.; Farrell, N. Chem. Eur. J., 2003, 9, 713.
84. Brabec, V.; Kaspárková, J.; Vrána, O.; Nováková, O.; Cox, J.W.; Qu, Y.; Farrell, N. Biochemistry, 1999, 38, 6781.
85. Wheate, N.J.; Evison, B.J.; Herlt, A.J.; Phillips, D.R.; Collins, J.G. Dalton Trans., 2003, 3486.
86. Collins, J.G.; Wheate, N.J. J. Inorg. Biochem., 2004, 98, 1578.
87. Qu, Y.; Scarsdale, N.J.; Tran, M.-C.; Farrell, N.P. J. Biol. Inorg. Chem., 2003, 8, 19.
88. Hegmans, A.; Berners-Price, S.J.; Davies, M.S.; Thomas, D.S.; Humphreys, A.S.; Farrell, N. J. Am. Chem. Soc., 2004, 126, 2166.
89. Bancroft, D.P.; Lepre, C.A.; Lippard, S.J. J. Am. Chem. Soc., 1990, 12, 6860.
90. Qu, Y.; Farrell, N. J. Am. Chem. Soc., 1991, 113, 4851.
91. Davies, M.S.; Cox, J.W.; Berners-Price, S.J.; Barklage, W.; Qu, Y.; Farrell, N. Inorg. Chem., 2000, 39, 1710.
92. Davies, M.S.; Thomas, D.S.; Hegmans, A.; Berners-Price, S.J.; Farrell, N. Inorg. Chem., 2002, 41, 1101.
93. Cox, J.W.; Berners-Price, S.J.; Davies, M.S.; Qu, Y.; Farrell, N. J. Am. Chem. Soc., 2001, 123, 1316.
94. Kloster, M.B.G.; Hannis, J.C.; Muddiman, D.C.; Farrell, N. Biochemistry, 1999, 38, 14731.
95. Davies, M.S.; Berners-Price, S.J.; Cox, J.W.; Farrell, N. Chem. Comm., 2003, 122.
96. McGregor, T.D.; Hegmans, A.; Kaspárkova, J.; Neplechová, K.; Nováková, O.; Pesazová, H.; Vrána, O.; Brabec, V.; Farrell, N. J. Biol. Inorg. Chem., 2002, 7, 397.
97. Mellish, K.J.; Qu, Y.; Scarsdale, N.; Farrell, N. Nucl. Acids Res., 1997, 25, 1265.
98. Qu, Y.; Farrell, N. J. Inorg. Biochem., 1990, 40, 255.
99. Kloster, M.; Kostrhunova, H.; Zaludova, R.; Malina, J.; Kasparkova, J.; Brabec, V.; Farrell, N. Biochemistry, 2004, 43, 7776.
100. Farrell, N.; Qu, Y.; Roberts, J.D. Topics Biol. Inorg. Chem., 1999, 1, 99.
101. Roberts, J.D.; Van Houten, B.; Farrell, N.P. Nucl. Acids Res., 1989, 17, 9719.
102. Kaspárkova, J.; Nováková, O.; Vrána, O.; Farrell, N.; Brabec, V. Biochemistry, 1999, 38, 10997.
103. Qu, Y.; Bloemink, M.J.; Mellish, K.J.; Rauter, H.; Smeds, K.A.; Farrell, N. NATO Adv. Sci., 1997, 26, 435.
104. Zou, Y.; Van Houten, B.; Farrell, N. Biochemistry, 1994, 33, 5404.
105. Saludová, R.; Sákovská, A.; Kaspárkova, J.; Balcarová, Z.; Kleinwächter, V.; Vrána, O.; Farrell, N.; Brabec, V. Eur. J. Biochem., 1997, 246, 508.
106. Kaspárkova, J.; Zehnulova, J.; Farrell, N.; Brabec, V. J. Biol. Chem., 2002, 277, 48076. ,
107. Zehnulova, J.; Kaspárkova, J.; Farrell, N.; Brabec, V. J. Biol. Chem., 2001, 276, 22191.
108. Bloemink, M.J.; Reedijk, J.; Farrell, N.; Qu, Y.; Stetsenko, A.I. Chem Comm., 1992, 1002.
109. Kaspárková, J.; Mellish, K.J.; Qu, Y.; Brabec, V.; Farrell, N. Biochemistry, 1996, 35, 16705.
110. Hofr, C.; Farrell, N.; Brabec, V. Nucl. Acids Res., 2001, 29, 2034.
111. Kaspárkova, J.; Farrell, N.; Brabec, V. J. Biol. Chem., 2000, 275, 15789.
112. Malfoy, B.; Hartman, B.; Leng, M. Nucl. Acids Res., 1981, 9, 5659.
113. Ushay, H.M.; Santella, R.M.; Caradonna, J.P.; Grunberger, D.; Lippard, S.J. Nucl. Acids Res., 1982, 10, 3573.
114. Johnson, A.; Qu, Y.; Van Houten, B.; Farrell, N. Nucl. Acids Res., 1992, 20, 1697.
115. Yang, D.; van Boom, S.S.G.E.; Reedijk, J.; van Boom, J.H.; Farrell, N.; Wang, A.H.-J. Nat. Struct. Biol., 1995, 2, 577.
116. Qu, Y.; Farrell, N. Inorg. Chim. Acta, 1996, 245, 265.
117. Wu, P.K.; Kharatishvili, M.; Qu, Y.; Farrell, N. J. Inorg. Biochem., 1996, 63, 9.
118. McGregor, T.D.; Balcarová, Z.; Qu, Y.; Tran, M.-C.; Zaludová, R.; Brabec, V.; Farrell, N. J. Inorg. Biochem., 1999, 77, 43.
119. McGregor, T.D.; Bousfield, W.; Qu, Y.; Farrell, N. J. Inorg. Biochem., 2002, 91, 212.
120. Farrell, N. In Advances in DNA Sequence Specific Agents Vol. 2, JAI Press: New York, 1996, pp. 187-216.
121. Farrell, N.; Appleton, T.G.; Qu, Y.; Roberts, J.D.; Soares Fontes, A.P.; Skov, K.A.; Wu, P.; Zou, Y. Biochemistry, 1995, 34, 15480.
122. Jin, V.X.; Ranford, J.D. Inorg. Chim. Acta, 2000, 304, 38.
123. Temple, M.D.; McFadyen, W.D.; Holmes, R.J.; Denny, W.A.; Murray, V. Biochemistry, 2000, 39, 5593.
124. Holmes, R.J.; McKeage, M.J.; Murray, V.; Denny, W.A.; McFadyen, W.D. J. Inorg. Biochem., 2001, 85, 209.
125. Cai, L.; Keunpoong, L.; Ren, S.; Cadena, R.S.; Beck, W.T. J. Med. Chem., 2001, 44, 2959.
126. Locher, G. L. Am. J. Roentgenol. Radium Ther., 1936, 36, 1.
127. Woodhouse, S.L.; Rendina, L.M. Chem. Comm., 2001, 2464.
128. Todd, J.A.; Rendina, L.M. Inorg. Chem., 2002, 41, 3331.
129. Todd, J.A.; Rendina, L.M. Inorg. Chem. Comm., 2004, 7, 289.
130. Woodhouse, S.L.; Rendina, L.M. Dalton Trans., 2004, 21, 3669.
131. Wheate, N.J.; Day, A.I.; Blanch, R.J.; Arnold, A.P.; Cullinane, C.; Collins, J.G. Chem. Comm., 2004, 1424.